Depixus

Executive Summary

Depixus is a French life-science tools company founded in 2020, pioneering a novel magnetic force spectroscopy (MFS) platform that enables real-time, single-molecule analysis of thousands of biomolecular interactions in parallel. Its flagship product, the MAGNA One instrument, offers unprecedented insights into molecular dynamics and heterogeneity, which could significantly accelerate drug discovery and development. The company addresses a critical need in the pharmaceutical industry for deeper understanding of molecular mechanisms, particularly in complex diseases. While still in early commercialization stages, Depixus's technology has the potential to differentiate itself in the competitive single-molecule analysis market. The company is privately held and has not disclosed funding details, but its innovative approach positions it as a promising player in the genomics and drug discovery tools space.

Upcoming Catalysts (preview)

• Q2 2026Commercial launch and initial customer adoption of MAGNA One70% success
• Q3 2026Strategic partnership with a major pharmaceutical company for drug discovery applications50% success
• Q4 2026Series A or Series B funding round to support scaling and commercial expansion65% success